THE ROLE OF FERRITIN IN EARLY DETECTION OF ANTHRACYCLINE INDUCED CARDIAC DYSFUNCTION IN BREAST CANCER

Clicks: 8
ID: 330932
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #323 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Cancer therapy-related cardiac dysfunction (CTRCD), defined as >15% reduction in Global Longitudinal Strain (GLS), may occur before conventional biomarkers change. Troponin T and NT-proBNP are widely used. Ferritin reflects iron-mediated oxidative stress and inflammation but its predictive value in anthracycline-induced CTRCD remains unclear. This study aimed to evaluated ferritin and other biochemical and metabolic factors as predictors of GLS reduction in breast cancer patients receiving anthracyclines. Methods In 2024, from March until December, 16 breast cancer patients with CTRCD were included in this study. Ferritin, Troponin T, NT-proBNP, serum iron, TIBC, and transferrin saturation were measured before and after the third chemotherapy cycle. GLS reduction was evaluated. Multivariate regression identified predictors of subclinical cardiac dysfunction. Results The mean age of 16 patients was 51.06 ± 8.13 years, with a mean of BMI of 23.40 ± 5.70 kg/m². Hypertension was the most common comorbidity (31%), followed by diabetes mellitus (12%) and dyslipidemia (12%). Ferritin increased from 260.3 ± 174.9 ng/mL to 419.1 ± 298.1 ng/mL (p = 0.021) and showed strong correlation with GLS reduction. Troponin T rose modestly. NT-proBNP, serum iron, and TIBC remained stable. Multivariate regression identified ferritin (p = 0.042), diabetes (p = 0.006), and BMI (p = 0.041) as independent predictors. NT-proBNP and TIBC showed trends toward significance (R² = 0.95, p = 0.036). Conclusion Ferritin is a strong early marker of subclinical CTRCD. Alongside NT-proBNP, Troponin T, TIBC, BMI, and diabetes, ferritin can identify high-risk breast cancer patients early and guide preventive strategies against anthracycline cardiotoxicity.Figure 1.Partial regression plots show ferritin, Troponin T, NT-proBNP, TIBC, diabetes, and BMI associations with GLS reduction >15%, with ferritin exhibiting the strongest correlation (R² = 0.952, p = 0.036).
Reference Key
openalex_W7220362760 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors F Soniya, M Lerista, I Puspita, M R Felani, A E Tondas
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.010
URL
https://doi.org/10.1093/eurheartjsupp/suag119.010
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.